Clinical Trials Browser

Approved for marketing × Capecitabine × Clear all

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing

HER2-positive Breast Cancer